AI in Drug Developement: Transforming Drug Discovery and Repurposing Online Del 22/11/2024 11:00 to 22/11/2024 Healthcare Innovative drugs Communication
INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer In... 29/10/2024 Healthcare Access to innovation Innovative drugs VC funding led by imec.xpand, with significant participation from the EIC Fund (venture arm of the European Innovation... Partners - Asabys Partners
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European ... 23/10/2024 Healthcare Access to innovation Innovative drugs Partners - THERIVA BIOLOGICS S.L.
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic ... 18/10/2024 Healthcare Innovative drugs ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1 Partners - ARTHEx Biotech
ORYZON announces formal grant of key European patent for vafidemstat 14/10/2024 Healthcare Innovative drugs International EU projects For the treatment of aggression and social withdrawal. Partners - Oryzon Genomics
AEMPS approves Peaches' clinical trial with selective secretomes to treat COVID-19-associa... 10/10/2024 Healthcare Innovative drugs Personalized medicine Advanced therapies Peaches starts its phase I-II pilot trial to obtain an advanced biologic drug that will help combat cytokine storm, a... Partners - PEACHES BIOTECH S.L.
"ApToll is an immune modulator to treat ischaemic stroke in the acute phase. We have suc... 10/10/2024 Healthcare Innovative drugs David Segarra, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring... Partners - GENESIS Biomed
AEMPS approves Peaches clinical trial with selective secretomes to treat COVID-19-associat... 08/10/2024 Healthcare Innovative drugs Personalized medicine Peaches starts its phase I-II pilot trial to obtain an advanced biologic drug that will help combat cytokine storm, a... Partners - PEACHES BIOTECH S.L.
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase I... 01/10/2024 Healthcare Innovative drugs Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2. Partners - Oryzon Genomics
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-... 25/09/2024 Healthcare Innovative drugs Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain... Partners - THERIVA BIOLOGICS S.L.
